Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder
March 22, 2021 14:30 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR
March 19, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S....
Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2
March 17, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Vaccine Candidate TNX-1800 Protected Both Upper and Lower Airways After Challenge with SARS-CoV-2, Suggesting an Ability to Block Forward Transmission TNX-1800 is Based on a Proprietary Vaccine...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 15, 2021 16:45 ET
|
Tonix Pharmaceuticals Holding Corp.
Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim...
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia
March 15, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Enrollment Continues in Phase 3 RALLY Study, with Interim Analysis of the First 50 Percent of Participants Expected Third Quarter 2021 Topline Results of Approximately 670 Participants in RALLY...
Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences
March 09, 2021 07:30 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 04, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has...
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
February 11, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond ...
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
February 10, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
February 09, 2021 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the...